西尼地平治疗轻、中度原发性高血压临床疗效及安全性观察  

Observation of Clinical Efficacy and Safety of Mild and Moderate Primary Hypertension Treated with Cilnidipine

作　　者：张慧[1] 赵秀丽[1] 胡大一[1] 

机构地区：[1]首都医科大学附属北京同仁医院,北京市100730

出　　处：《中国医院用药评价与分析》2003年第1期39-40,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的 :评价西尼地平治疗高血压的有效性和安全性。方法 :16例原发性轻、中度高血压患者入组本研究 ,应用西尼地平治疗 2 4wk。西尼地平起始剂量为 5mg,1日 1次 ,1mo后根据舒张压情况可将西尼地平剂量调整至 10mg,1日 1次。结果 :与治疗前相比 ,收缩压和舒张压的下降均具有显著性差异。 2 4wk时收缩压和舒张压分别下降了 13.38mmHg和 12 75mmHg。心率无改变。不良反应轻微。结论 :西尼地平是新型第三代双通道二氢吡啶类钙通道阻滞剂 ,在治疗轻、中度高血压过程中安全有效 ,不良反应轻微 ,患者能很好耐受。OBJECTIVE:To evaluate efficacy and safety of hypertension treated with cilnidipine. METHODS:16 patients with mild and moderate primary hypertension were enrolled in this study. They were treated with cilnidipine for 24 weeks. Initial dose was 5mg/d. One month later, according to the value of diastolic pressure, the dosage of the drug could be adjusted to 10mg/d.RESULTS:Decreas in both systolic and diastolic pressure had obvious differences compared with that before treatment. By 24th week, systolic and diastolic pressure by 13.38mmHg and 12.75mmHg respectively. There was no change in heart rate, and ADR was slight. CONCLUSION:This drug is the new type 3rd generation Calcium Channel Blockers (1,4DHP),which is safe and efficent for the treatment of mild and moderate hypertension with slight ADR.So it can be well tolerated by the patients.

关 键 词：原发性高血压 西尼地平 治疗 疗效 安全性 诊断 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]